<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02461264</url>
  </required_header>
  <id_info>
    <org_study_id>14-128</org_study_id>
    <nct_id>NCT02461264</nct_id>
  </id_info>
  <brief_title>Transfusion Strategy in Hematological Intensive Care Unit</brief_title>
  <acronym>1VERSUS2CGR</acronym>
  <official_title>Randomized Multicenter Trial of Two Transfusion Strategies for Patient Receiving Chemotherapy for Acute Leukemia or Hematopoietic Stem Cells With Medico-economic Evaluation of Cost Minimization.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Caen</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Caen</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Patients with acute hematological disease (acute leukemia, aplastic anemia, hematopoietic
      stem cells autologous or allogeneic ...) and hospitalized in an intensive care unit
      hematology require compensation of anemia and thrombocytopenia by blood transfusions of red
      blood packed cells (RBP) or platelet concentrates (PC).The AFSSAPS (Agence Française de
      Sécurité Sanitaire des Produits de Santé) recommendations (2002) specify the need to
      transfuse 2 RBP in case of symptomatic anemia usually for a hemoglobin between 6 and 10 g /
      dL. These recommendations allow to transfuse a single RBP for very elderly patients or in
      cases of associated heart disease (heart failure). A recent development (2012) on
      post-transfusion pulmonary edema overload recommends transfusion unit by unit for high risk
      patients.

      More recently, a Swiss team has historically compared transfusion policies in 2 139 patients
      with hematological malignancies. The first group received 2 RBP transfusion in case of
      symptomatic anemia or hemoglobin level &lt;6 g / dL. The other group only received 1 RBP at each
      transfusion. In total 2212 units in 1548 transfusions were performed and the 1 RBP
      transfusion policy has resulted in a 25% decrease in the number of RBP used without any
      complication. In a prospective single-center pilot study, we showed that transfusing a single
      RBP was possible without increasing the side effects of anemia, without complications and
      allow an overall reduction in consumption of red blood cell units.

      Several meta-analyzes reported in intensive care or bleeding situations that a restrictive
      use of transfusions significantly reduces cardiac events, bleeding, bacterial infections and
      mortality. The number of patient to be treated to prevent one death is 33.

      The main objective is to demonstrate in a randomized trial that the restrictive strategy
      (transfusion of a single unit at each transfusion) is not inferior to the liberal strategy
      (transfusion of 2 unit at each transfusion) in terms of severe complication. Transfusion are
      performed in case of hemoglobin level &lt;8g/dL.

      Key secondary objectives are to reduce the number of RBP used and the cost of hospitalization
      with a comparison of complications/mortality in the 2 groups.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>January 2016</start_date>
  <completion_date type="Anticipated">September 2018</completion_date>
  <primary_completion_date type="Anticipated">June 2018</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of severe complications (grade 3 or more)</measure>
    <time_frame>up to 1 month after the last day of hospitalization</time_frame>
    <description>complications are defined as: stroke, transient ischemic attack, acute coronary syndrome, heart failure, arrhythmias or conduction cardiac disease, deep vein thrombosis, pulmonary embolism, elevated troponin, transfer to intensive care unit, death from any cause, new or progressive radiographic infiltrates, infections related to transfusion.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>number of RBP transfused</measure>
    <time_frame>up to 1 month after the last day of hospitalization</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of bleeding</measure>
    <time_frame>up to 1 month after the last day of hospitalization</time_frame>
    <description>number of patient with bleeding grade 3 or more</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Transfusion related events</measure>
    <time_frame>up to 1 month after the last day of hospitalization</time_frame>
    <description>Number of transfusion related events defined as any complication that the physician declared to be related to the transfusion (fever, infection, pulmonary edema..)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to erythroid recovery</measure>
    <time_frame>up to 1 month after the last day of hospitalization</time_frame>
    <description>Time from randomization to last transfusion</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life</measure>
    <time_frame>up to 1 month after the last day of hospitalization</time_frame>
    <description>Functional Assessment of Cancer Therapy and QLC30</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>time of aplasia</measure>
    <time_frame>up to 1 month after the last day of hospitalization</time_frame>
    <description>from 1st day with neutrophils&lt;500 to first day with neutrophils&gt;500/mm3</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Transfusion performance</measure>
    <time_frame>up to 24 hours</time_frame>
    <description>difference between hemoglobin level before and 24 hours after transfusion</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>transfusion in out patient</measure>
    <time_frame>up to 1 month after the last day of hospitalization</time_frame>
    <description>number of RBP transfused after leaving the unit</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Failure to respect the randomisation arm</measure>
    <time_frame>up to 1 month after the last day of hospitalization</time_frame>
    <description>number of patient in arm B that received 2 RBP instead of single RBP</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">230</enrollment>
  <condition>Transfusion Related Complication</condition>
  <arm_group>
    <arm_group_label>ARM A</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Two packed red blood cells will be transfused in patient with anemia defined as a hemoglobin level below 8 g / dL. Clinical and biological monitoring will be carried out later each day. If the hemoglobin is &lt;8 g / dL, two new packed red blood cells are transfused and so on.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ARM B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single red blood packed cells Transfusion will be administered in patient with anemia defined as a hemoglobin level below 8 g/dL. Clinical and biological monitoring will be carried out later each day. If the hemoglobin is &lt;8 g / dL, a single unit is transfused and so on.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Single red blood packed cells Transfusion</intervention_name>
    <arm_group_label>ARM B</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Two packed red blood cells Transfusion</intervention_name>
    <arm_group_label>ARM A</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Inpatients with either acute leukemia patient receiving intensive chemotherapy or
             autologous transplantation for lymphoma, allogeneic stem cell transplantation

        Exclusion Criteria:

          -  ischemic heart failure

          -  acute promyelocytic leukemia

          -  ALKERAN autologous conditioning (myeloma patient)

          -  disseminated intravascular coagulation

          -  hemorrhagic syndrome

          -  stroke

          -  any vital distress at diagnosis

          -  creatinine clearance &lt;50 ml/min

          -  liver disease with ALT (alanine aminotransferase)/AST(aspartate aminotransferase) ≥2.5
             ULN (upper limit of normal) (except if related to tumor)

          -  pregnant female

          -  autoimmune hemolytic anemia
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>University Hospital</name>
      <address>
        <city>Caen</city>
        <zip>14000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sylvain P Chantepie, MD</last_name>
      <phone>+33231272073</phone>
      <email>chantepie-s@chu-caen.fr</email>
    </contact>
    <investigator>
      <last_name>Sylvain P Chantepie, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <results_reference>
    <citation>Shander A, Hofmann A, Ozawa S, Theusinger OM, Gombotz H, Spahn DR. Activity-based costs of blood transfusions in surgical patients at four hospitals. Transfusion. 2010 Apr;50(4):753-65. doi: 10.1111/j.1537-2995.2009.02518.x. Epub 2009 Dec 9.</citation>
    <PMID>20003061</PMID>
  </results_reference>
  <results_reference>
    <citation>Madjdpour C, Spahn DR. Allogeneic red blood cell transfusions: efficacy, risks, alternatives and indications. Br J Anaesth. 2005 Jul;95(1):33-42. Epub 2004 Oct 14. Review.</citation>
    <PMID>15486006</PMID>
  </results_reference>
  <results_reference>
    <citation>Wang JK, Klein HG. Red blood cell transfusion in the treatment and management of anaemia: the search for the elusive transfusion trigger. Vox Sang. 2010 Jan;98(1):2-11. doi: 10.1111/j.1423-0410.2009.01223.x. Epub 2009 Aug 4. Review.</citation>
    <PMID>19682346</PMID>
  </results_reference>
  <results_reference>
    <citation>Ma M, Eckert K, Ralley F, Chin-Yee I. A retrospective study evaluating single-unit red blood cell transfusions in reducing allogeneic blood exposure. Transfus Med. 2005 Aug;15(4):307-12.</citation>
    <PMID>16101808</PMID>
  </results_reference>
  <results_reference>
    <citation>Leal-Noval SR, Muñoz-Gómez M, Jiménez-Sánchez M, Cayuela A, Leal-Romero M, Puppo-Moreno A, Enamorado J, Arellano-Orden V. Red blood cell transfusion in non-bleeding critically ill patients with moderate anemia: is there a benefit? Intensive Care Med. 2013 Mar;39(3):445-53. doi: 10.1007/s00134-012-2757-z. Epub 2012 Nov 27.</citation>
    <PMID>23184038</PMID>
  </results_reference>
  <results_reference>
    <citation>Watkins TC, Clark CT. Critically ill and septic patient: is red blood cell transfusion adding to the Domino Effect? J Infus Nurs. 2013 Mar-Apr;36(2):116-21. doi: 10.1097/NAN.0b013e318282a6cd.</citation>
    <PMID>23455973</PMID>
  </results_reference>
  <results_reference>
    <citation>Robitaille N, Lacroix J, Alexandrov L, Clayton L, Cortier M, Schultz KR, Bittencourt H, Duval M. Excess of veno-occlusive disease in a randomized clinical trial on a higher trigger for red blood cell transfusion after bone marrow transplantation: a canadian blood and marrow transplant group trial. Biol Blood Marrow Transplant. 2013 Mar;19(3):468-73. doi: 10.1016/j.bbmt.2012.12.002. Epub 2012 Dec 7.</citation>
    <PMID>23220014</PMID>
  </results_reference>
  <results_reference>
    <citation>Berger MD, Gerber B, Arn K, Senn O, Schanz U, Stussi G. Significant reduction of red blood cell transfusion requirements by changing from a double-unit to a single-unit transfusion policy in patients receiving intensive chemotherapy or stem cell transplantation. Haematologica. 2012 Jan;97(1):116-22. doi: 10.3324/haematol.2011.047035. Epub 2011 Sep 20.</citation>
    <PMID>21933858</PMID>
  </results_reference>
  <results_reference>
    <citation>Carson JL, Carless PA, Hebert PC. Transfusion thresholds and other strategies for guiding allogeneic red blood cell transfusion. Cochrane Database Syst Rev. 2012 Apr 18;(4):CD002042. doi: 10.1002/14651858.CD002042.pub3. Review. Update in: Cochrane Database Syst Rev. 2016 Oct 12;10 :CD002042.</citation>
    <PMID>22513904</PMID>
  </results_reference>
  <results_reference>
    <citation>Salpeter SR, Buckley JS, Chatterjee S. Impact of more restrictive blood transfusion strategies on clinical outcomes: a meta-analysis and systematic review. Am J Med. 2014 Feb;127(2):124-131.e3. doi: 10.1016/j.amjmed.2013.09.017. Epub 2013 Oct 7. Review.</citation>
    <PMID>24331453</PMID>
  </results_reference>
  <results_reference>
    <citation>Mear JB, Chantepie SP, Gac AC, Bazin A and Reman O. A restrictive transfusion Strategy allow a reduction of the number of packed red blood cells: result of a pilot study; Abstract 2217; PH-AB153 Bone marrow Transplant 2014.</citation>
  </results_reference>
  <verification_date>August 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 28, 2015</study_first_submitted>
  <study_first_submitted_qc>June 2, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 3, 2015</study_first_posted>
  <last_update_submitted>August 30, 2016</last_update_submitted>
  <last_update_submitted_qc>August 30, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 1, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University Hospital, Caen</investigator_affiliation>
    <investigator_full_name>Sylvain CHANTEPIE</investigator_full_name>
    <investigator_title>Hematologist</investigator_title>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

